利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.018 秒)

    Peptide based inhibition of caPCNA interaction in cancer
    1.
    发明授权
    Peptide based inhibition of caPCNA interaction in cancer 有权
    基于肽的抑制癌症中的CaPCNA相互作用

    公开(公告)号：US09187526B2

    公开(公告)日：2015-11-17

    申请号：US14182550

    申请日：2014-02-18

    申请人： Robert J. Hickey ,  Linda H. Malkas

    发明人： Robert J. Hickey ,  Linda H. Malkas

    IPC分类号： A61K38/03 ,  C07K4/00 ,  C07K7/06 ,  C07K14/47

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/4738

    摘要： Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.

    摘要翻译： 衍生自增殖细胞核抗原（caPCNA，也称为csPCNA）或来自nmPCNA相互作用蛋白的癌症特异性同种型的肽干扰细胞内蛋白质 - 蛋白质相互作用，从而导致癌症增殖潜力的降低。 这些肽用作治疗组合物以减少癌细胞的增殖并增加现有的化学治疗方法。

    PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER
    5.
    发明申请
    PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER 审中-公开
    基于肽的抑制大鼠caPCNA相互作用

    公开(公告)号：US20140296156A1

    公开(公告)日：2014-10-02

    申请号：US14182550

    申请日：2014-02-18

    申请人： Linda H. Malkas ,  Robert J. Hickey

    发明人： Robert J. HICKEY ,  Linda H. MALKAS

    IPC分类号： C07K7/06

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/4738

    摘要： Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.

    摘要翻译： 衍生自增殖细胞核抗原（caPCNA，也称为csPCNA）或来自nmPCNA相互作用蛋白的癌症特异性同种型的肽干扰细胞内蛋白质 - 蛋白质相互作用，从而导致癌症增殖潜力的降低。 这些肽用作治疗组合物以减少癌细胞的增殖并增加现有的化学治疗方法。

    Peptide based inhibition of caPCNA interaction in cancer
    6.
    发明授权
    Peptide based inhibition of caPCNA interaction in cancer 有权
    基于肽的抑制癌症中的CaPCNA相互作用

    公开(公告)号：US08653039B2

    公开(公告)日：2014-02-18

    申请号：US12279028

    申请日：2007-02-16

    申请人： Robert J. Hickey ,  Linda H. Malkas

    发明人： Robert J. Hickey ,  Linda H. Malkas

    IPC分类号： A61K38/08 ,  A61K38/10 ,  A61P35/00 ,  A61K39/395 ,  G01N33/574

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/4738

    摘要： Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.

    摘要翻译： 衍生自增殖细胞核抗原（caPCNA，也称为csPCNA）或来自nmPCNA相互作用蛋白的癌症特异性同种型的肽干扰细胞内蛋白质 - 蛋白质相互作用，从而导致癌症增殖潜力的降低。 这些肽用作治疗组合物以减少癌细胞的增殖并增加现有的化学治疗方法。